Related Experiment Video
Updated: Jun 16, 2026

Skeletal Muscle Neurovascular Coupling, Oxidative Capacity, and Microvascular Function with 'One Stop Shop' Near-infrared Spectroscopy
Published on: February 20, 2018
The skeletal muscle VEGF mRNA response to acute exercise in patients with chronic heart failure
Fabio Esposito1, Odile Mathieu-Costello, Pauline L Entin
1Department of Sport, Nutrition and Health Sciences, University of Milan, Via Colombo 71, Milan, Italy. fabio.esposito@unimi.it
Abstract:
In seven patients with chronic heart failure (CHF) and six controls, we examined (a) resting and post-exercise muscle vascular endothelial growth factor (VEGF) mRNA levels and (b) their relationship with muscle structure and function. Muscle biopsies were taken after 30 min of single-leg knee-extensor exercise at 50% of maximum work rate (50% WR(max)) from both the exercised and rested legs. Muscle blood flow (.Q) and O(2) uptake .VO(2) were measured during exercise. Resting VEGF mRNA levels were not different between patients and controls and both groups upregulated VEGF mRNA equally in response to acute exercise. Patients had lower .Q, .VO(2), and mitochondrial density but similar capillarity and fiber area. These findings reveal a normal basal level of muscle VEGF mRNA, its appropriate upregulation in response to acute exercise and, despite increased vascular resistance during exercise, a normal skeletal muscle vascular structure in patients with CHF.
Related Concept Videos
Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Pathophysiology of Heart Failure
Heart Failure III: Clinical Manifestations
Heart Failure Drugs: Inotropic Agents

